Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT06717958

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Led by Technische Universität Dresden · Updated on 2025-07-02

76

Participants Needed

12

Research Sites

241 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days

CONDITIONS

Official Title

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasia (MDS) with an IDH1 mutation
Not Eligible

You will not qualify if you...

  • Active graft versus host disease (GvHD) grade III-IV requiring steroids greater than 1 mg/kg prednisolone equivalent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Universitätsklinikum Aachen

Aachen, Germany

Not Yet Recruiting

2

Technische Universitaet Dresden, Medizinische Klinik und Poliklinik I

Dresden, Germany

Not Yet Recruiting

3

Universitätsklinikum Essen

Essen, Germany

Not Yet Recruiting

4

Martin-Luther-Universitaet Halle-Wittenberg

Halle, Germany

Actively Recruiting

5

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

Not Yet Recruiting

6

Universitätsklinikum Jena

Jena, Germany

Not Yet Recruiting

7

Universitätsklinikum Schleswig-Holstein

Kiel, Germany

Actively Recruiting

8

Universität Leipzig

Leipzig, Germany

Not Yet Recruiting

9

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

München, Germany

Not Yet Recruiting

10

Universität Münster

Münster, Germany

Not Yet Recruiting

11

Rostock University Medical Center

Rostock, Germany

Not Yet Recruiting

12

Universitaetsklinikum Ulm

Ulm, Germany

Not Yet Recruiting

Loading map...

Research Team

J

Jan Moritz Middeke, Dr. med.

CONTACT

F

Friedrich Stölzel, Prof. Dr. med.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation | DecenTrialz